Webinars

To the casual observer, the optimistic discussion swirling around Humira biosimilars seems as if these competitor drugs will provide some relief to the country’s specialty drug problem. Unfortunately, the opposite is true; and our best opportunity in a generation to break the PBM stranglehold will be wasted.

Watch